日本のヒトマイクロバイオーム市場レポート：製品、用途、疾患タイプ、地域別、2025年～2033年

日本のヒトマイクロバイオーム市場規模は2024年に2,140万米ドルに達しました。今後、IMARC Groupは、市場は2033年までに1億6,750万米ドルに達し、2025年から2033年にかけて23.70%の成長率（CAGR）を示すと予測しています。生命科学とバイオテクノロジーの分野における数多くの進歩と、バイオテクノロジーインフラ全体のアップグレードに向けた政府機関による投資の増加が、主に市場成長を促進しています。

本レポートで扱う主な質問

• 日本のヒトマイクロバイオーム市場はこれまでどのように推移し、今後どのように推移するのか？
• COVID-19が日本のヒトマイクロバイオーム市場に与えた影響は？
• 日本のヒトマイクロバイオーム市場の製品別区分は？
• 日本のヒトマイクロバイオーム市場の用途別区分は？
• 日本のヒトマイクロバイオーム市場の疾患タイプ別区分は？
• 日本のヒトマイクロバイオーム市場のバリューチェーンにおける様々なステージとは？
• 日本のヒトマイクロバイオームにおける主要な促進要因と課題は何か？
• 日本のヒトマイクロバイオーム市場の構造と主要プレーヤーは？
• 日本のヒトマイクロバイオーム市場における競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

• 調査の目的
• ステークホルダー
• データソース
• 市場推定
• 調査手法

第3章 エグゼクティブサマリー

第4章 日本のヒトマイクロバイオーム市場- イントロダクション

• 概要
• 市場力学
• 業界動向
• 競合情報

第5章 日本のヒトマイクロバイオーム市場情勢

• 過去および現在の市場動向（2019～2024年）
• 市場予測（2025～2033年）

第6章 日本のヒトマイクロバイオーム市場- 製品別の内訳

• プロバイオティクス
• プレバイオティクス
• 診断検査
• 薬剤
• 医療食品
• その他

第7章 日本のヒトマイクロバイオーム市場- 用途別の内訳

• 治療
• 診断

第8章 日本のヒトマイクロバイオーム市場- 疾患タイプ別の内訳

• 肥満
• 糖尿病
• 自己免疫疾患
• がん
• 胃腸障害
• 中枢神経系疾患
• その他

第9章 日本のヒトマイクロバイオーム市場- 競合情勢

• 概要
• 市場構造
• 市場企業のポジショニング
• 主要成功戦略
• 競合ダッシュボード
• 企業評価象限

第10章 主要企業のプロファイル

第11章 日本のヒトマイクロバイオーム市場- 業界分析

• 促進要因・抑制要因・機会
• ポーターのファイブフォース分析
• バリューチェーン分析

第12章 付録

Japan human microbiome market size reached USD 21.4 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 167.5 Million by 2033, exhibiting a growth rate (CAGR) of 23.70% during 2025-2033. Numerous advancements in the field of life science and biotechnology, along with the rising investments by government bodies in upgrading the overall biotechnology infrastructures, are primarily driving the market growth.

The human microbiome encompasses the genetic material present within a diverse array of microorganisms contained in the collective genetic makeup, known as the metagenome, of humans. It comprises a multitude of microorganisms, including bacteria, fungi, protozoans, non-living viruses, and various single-celled organisms. These microorganisms exert an influence on human physiology and play a role in either enhancing or compromising metabolic and immune functions. They are distributed throughout human tissues and are subjects of study for advancements in medicine and analytical methodologies. Microbiomes find applications in areas such as probiotics, prebiotics, pharmaceutical drugs, and diagnostic and therapeutic systems tailored to address various medical conditions, including but not limited to diabetes, obesity, cancer, as well as disorders related to metabolism, the gastrointestinal system, the nervous system (both central and peripheral), and autoimmune diseases.

Japan Human Microbiome Market Trends:

In the Japanese market context, the growth of the industry is being propelled by several key factors. One significant driver is the increasing incidence of chronic lifestyle-related diseases and infections resulting from microbial imbalances, a trend observed worldwide. Additionally, the growing elderly population in Japan, which is more susceptible to such health conditions, is contributing to market expansion. Furthermore, the market's growth is attributed to the heightened focus on developing human microbiome therapies with enhanced effectiveness. For instance, researchers are formulating specific combinations of human gut microbiomes to treat various gastrointestinal disorders more effectively. The outbreak of the COVID-19 pandemic has also spurred market growth, as extensive research is underway to examine lung microbiomes, assess infection severity, and develop suitable therapeutics and vaccines. Moreover, advancements like the creation of microbiome-based therapies tailored to specific targets are fostering market expansion. Other contributing factors include robust research and development (R&D) activities and significant growth in the pharmaceutical sector, particularly in developing economies, all of which are poised to propel the market forward in the coming years.

Japan Human Microbiome Market Segmentation:

Product Insights:

• Probiotics
• Prebiotics
• Diagnostic Tests
• Drugs
• Medical Food
• Others

Application Insights:

• Therapeutics
• Diagnostics

Disease Type Insights:

• Obesity
• Diabetes
• Autoimmune Disorders
• Cancer
• Gastrointestinal Disorders
• Central Nervous System Disorders
• Others

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

• How has the Japan human microbiome market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the Japan human microbiome market?
• What is the breakup of the Japan human microbiome market on the basis of product?
• What is the breakup of the Japan human microbiome market on the basis of application?
• What is the breakup of the Japan human microbiome market on the basis of disease type?
• What are the various stages in the value chain of the Japan human microbiome market?
• What are the key driving factors and challenges in the Japan human microbiome?
• What is the structure of the Japan human microbiome market and who are the key players?
• What is the degree of competition in the Japan human microbiome market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Human Microbiome Market - Introduction

• 4.1 Overview
• 4.2 Market Dynamics
• 4.3 Industry Trends
• 4.4 Competitive Intelligence

5 Japan Human Microbiome Market Landscape

• 5.1 Historical and Current Market Trends (2019-2024)
• 5.2 Market Forecast (2025-2033)

6 Japan Human Microbiome Market - Breakup by Product

• 6.1 Probiotics
  • 6.1.1 Overview
  • 6.1.2 Historical and Current Market Trends (2019-2024)
  • 6.1.3 Market Forecast (2025-2033)
• 6.2 Prebiotics
  • 6.2.1 Overview
  • 6.2.2 Historical and Current Market Trends (2019-2024)
  • 6.2.3 Market Forecast (2025-2033)
• 6.3 Diagnostic Tests
  • 6.3.1 Overview
  • 6.3.2 Historical and Current Market Trends (2019-2024)
  • 6.3.3 Market Forecast (2025-2033)
• 6.4 Drugs
  • 6.4.1 Overview
  • 6.4.2 Historical and Current Market Trends (2019-2024)
  • 6.4.3 Market Forecast (2025-2033)
• 6.5 Medical Food
  • 6.5.1 Overview
  • 6.5.2 Historical and Current Market Trends (2019-2024)
  • 6.5.3 Market Forecast (2025-2033)
• 6.6 Others
  • 6.6.1 Historical and Current Market Trends (2019-2024)
  • 6.6.2 Market Forecast (2025-2033)

7 Japan Human Microbiome Market - Breakup by Application

• 7.1 Therapeutics
  • 7.1.1 Overview
  • 7.1.2 Historical and Current Market Trends (2019-2024)
  • 7.1.3 Market Forecast (2025-2033)
• 7.2 Diagnostics
  • 7.2.1 Overview
  • 7.2.2 Historical and Current Market Trends (2019-2024)
  • 7.2.3 Market Forecast (2025-2033)

8 Japan Human Microbiome Market - Breakup by Disease Type

• 8.1 Obesity
  • 8.1.1 Overview
  • 8.1.2 Historical and Current Market Trends (2019-2024)
  • 8.1.3 Market Forecast (2025-2033)
• 8.2 Diabetes
  • 8.2.1 Overview
  • 8.2.2 Historical and Current Market Trends (2019-2024)
  • 8.2.3 Market Forecast (2025-2033)
• 8.3 Autoimmune Disorders
  • 8.3.1 Overview
  • 8.3.2 Historical and Current Market Trends (2019-2024)
  • 8.3.3 Market Forecast (2025-2033)
• 8.4 Cancer
  • 8.4.1 Overview
  • 8.4.2 Historical and Current Market Trends (2019-2024)
  • 8.4.3 Market Forecast (2025-2033)
• 8.5 Gastrointestinal Disorders
  • 8.5.1 Overview
  • 8.5.2 Historical and Current Market Trends (2019-2024)
  • 8.5.3 Market Forecast (2025-2033)
• 8.6 Central Nervous System Disorders
  • 8.6.1 Overview
  • 8.6.2 Historical and Current Market Trends (2019-2024)
  • 8.6.3 Market Forecast (2025-2033)
• 8.7 Others
  • 8.7.1 Historical and Current Market Trends (2019-2024)
  • 8.7.2 Market Forecast (2025-2033)

9 Japan Human Microbiome Market - Competitive Landscape

• 9.1 Overview
• 9.2 Market Structure
• 9.3 Market Player Positioning
• 9.4 Top Winning Strategies
• 9.5 Competitive Dashboard
• 9.6 Company Evaluation Quadrant

10 Profiles of Key Players

• 10.1 Company A
  • 10.1.1 Business Overview
  • 10.1.2 Product Portfolio
  • 10.1.3 Business Strategies
  • 10.1.4 SWOT Analysis
  • 10.1.5 Major News and Events
• 10.2 Company B
  • 10.2.1 Business Overview
  • 10.2.2 Product Portfolio
  • 10.2.3 Business Strategies
  • 10.2.4 SWOT Analysis
  • 10.2.5 Major News and Events
• 10.3 Company C
  • 10.3.1 Business Overview
  • 10.3.2 Product Portfolio
  • 10.3.3 Business Strategies
  • 10.3.4 SWOT Analysis
  • 10.3.5 Major News and Events
• 10.4 Company D
  • 10.4.1 Business Overview
  • 10.4.2 Product Portfolio
  • 10.4.3 Business Strategies
  • 10.4.4 SWOT Analysis
  • 10.4.5 Major News and Events
• 10.5 Company E
  • 10.5.1 Business Overview
  • 10.5.2 Product Portfolio
  • 10.5.3 Business Strategies
  • 10.5.4 SWOT Analysis
  • 10.5.5 Major News and Events

11 Japan Human Microbiome Market - Industry Analysis

• 11.1 Drivers, Restraints, and Opportunities
  • 11.1.1 Overview
  • 11.1.2 Drivers
  • 11.1.3 Restraints
  • 11.1.4 Opportunities
• 11.2 Porters Five Forces Analysis
  • 11.2.1 Overview
  • 11.2.2 Bargaining Power of Buyers
  • 11.2.3 Bargaining Power of Suppliers
  • 11.2.4 Degree of Competition
  • 11.2.5 Threat of New Entrants
  • 11.2.6 Threat of Substitutes
• 11.3 Value Chain Analysis

12 Appendix